The obesity market is experiencing the most explosive growth in modern pharmaceutical history. With the rise of GLP-1 medications and a flood of semaglutide generics entering the market, the landscape is shifting from clinical discovery to a massive battle for market access and positioning.

In this episode of Game of Pharma, Lokesh sits down with Dr. Evan Nadler to decode the reality of this multi-billion-dollar therapeutic gold rush. We move past the consumer hype and break down the commercial realities of metabolic treatments.

In this episode, we cover:

• The GLP-1 Gold Rush: How the massive surge in obesity therapeutics is fundamentally changing pharmaceutical brand strategy.
• The Access Gap: Why the gap in treatment access is the single biggest opportunity (and hurdle) in healthcare right now.
• US vs. India: Comparing the structural differences between the US and Indian markets regarding metabolic therapies.
• Semaglutide Positioning: How pharma companies must position their branded generics to win the long game in a highly saturated market.

Whether you are a pharma marketer, brand manager, or healthcare executive, this conversation provides a strategic roadmap for navigating the biggest market shift in a generation.

#PharmaStrategy #GLP1 #ObesityMarket #PharmaMarketing #HealthcareInnovation #GameOfPharma #Semaglutide #BestPharmaPodcast

Dr. Nadler's LinkedIn: https://www.linkedin.com/in/evanpnadler/

Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/

Follow us on social media-

Website: https://gameofpharma.com/

Instagram: https://www.instagram.com/gameofpharma/

LinkedIn: https://www.linkedin.com/company/game-of-pharma/

Most people still think of China as just a generics producer. They are dead wrong. In just one decade, China has transformed from "copycat" to cutting-edge, and now Big Pharma is licensing assets from China, not just to it.

In this episode of Game of Pharma, Lokesh sits down with Dr. Julien Willard, former senior intelligence officer, health economist, and strategy executive at Accenture and IBM, to decode what is really happening in global biotech.

In this episode, we cover:

• The Big Shift: The single biggest sign China's pharma industry has fundamentally changed.
• The Gold Rush: Why global pharmaceutical companies are scrambling for Chinese biotech assets.
• Speed to Market: How clinical trials that take years in the West are being executed in months in Shanghai.
• The US vs. China: What Western pharma should (and absolutely shouldn't) copy from China's aggressive playbook.

If you make decisions in pharma, biotech, healthcare strategy, or investment, this conversation will change how you see the next decade of the industry.

#PharmaStrategy #BiotechTrends #ClinicalTrials #HealthcareInvestment #PharmaMarketing #DrugDevelopment #Pharma #Biotech #Pharmaceuticals #LifeSciences #HealthcareInnovation

Julien's LinkedIn: https://www.linkedin.com/in/julienwillard/

Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/

Follow us on social media-

Website: https://gameofpharma.com/

Instagram: https://www.instagram.com/gameofpharma/

LinkedIn: https://www.linkedin.com/company/game-of-pharma/

The future of clinical trials and pharmacovigilance relies heavily on patient data, but integrating that data is a massive challenge. With countless touchpoints and messy data formats across different devices, how can the pharmaceutical industry actually make sense of it all?

In this episode of Game of Pharma, Lokesh sits down with Marco Benitez, the CEO and founder of ROOK. Marco brings a wealth of experience to the table, having previously served as the Head of Medical Affairs at Roche before founding his tech company. We dive deep into how ROOK is solving the healthcare industry's fragmented data problem.

In this episode, we cover:

• The ROOK API Solution: How ROOK integrates data from over 300 wearables—including Apple Watch, Polar, Garmin, and Huawei—into a single API platform.
• Data Harmonization: The process of cleaning, standardizing, and harmonizing wearable data so that it is AI-ready for clinical trials and insurance companies.
• The Big Pivot: How the pandemic forced ROOK to pivot from a fitness club hardware model (tracking heart rates on screens) into a massive B2B data science company.
• Marco's Journey: Marco shares his incredible entrepreneurial path, starting from building a hospital algorithm at just 19 years old, to navigating Big Pharma, to pitching his multi-billion dollar data vision.
• 
  

If you are working in clinical trials, healthcare tech, or digital strategy, this episode provides a clear roadmap on how unstructured wearable data is being transformed into actionable insights.

#WearableTech #ClinicalTrials #DigitalHealth #PharmaInnovation #HealthData #GameOfPharma

Marco's LinkedIn: https://www.linkedin.com/in/marcobzg/

Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/

Follow us on social media-

Website: https://gameofpharma.com/

Instagram: https://www.instagram.com/gameofpharma/

LinkedIn: https://www.linkedin.com/company/game-of-pharma/